SynCore Biotechnology Co.,Ltd (TPEX:4192)

Market Cap	771.87M -38.8%
Revenue (ttm)	26.26M +14.5%
Net Income	-46.41M
EPS	-1.32
Shares Out	35.17M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,435
Average Volume	13,553
Open	21.50
Previous Close	22.00
Day's Range	21.50 - 22.00
52-Week Range	21.50 - 36.20
Beta	0.33
RSI	18.26
Earnings Date	Jan 27, 2026

About TPEX:4192

SynCore Biotechnology Co.,Ltd, engages in development and sale of food advisory, medicine inspection, and biotechnology service in Taiwan. The company is involved in the development of SB01, an injectable anti-cancer new ingredient (NCE) that is in Phase II clinical trials for the treatment of head and neck cancer; and SB02, an anti-cancer NCE, which is in preclinical research for use in the treatment of stomach cancer. It also offers SB03-Veregen, an ointment for the treatment of patients with external genital and perianal warts EGW; and SB04,...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 40
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4192

Financial Performance

In 2024, TPEX:4192's revenue was 23.34 million, an increase of 15.55% compared to the previous year's 20.20 million. Losses were -54.28 million, 42.2% more than in 2023.